Details of Disease

General Information of Disease (ID: DISQ8G5S)

Disease Name	Gastroesophageal reflux disease
Synonyms	gastroesophageal reflux, pediatric; gastroesophageal reflux, paediatric; ger; gastro-esophageal reflux; Gastresophageal reflux; GERD; gastroesophageal reflux; GERD - gastro-esophageal reflux disease; gastroesophageal reflux disease; acid reflux
Disease Class	DA22: Gastro-oesophageal reflux disease
Definition	A chronic disorder characterized by reflux of the gastric and/or duodenal contents into the distal esophagus. It is usually caused by incompetence of the lower esophageal sphincter. Symptoms include heartburn and acid indigestion. It may cause injury to the esophageal mucosa.
Disease Hierarchy	DISYKSRF: Genetic disease DISJLJZ9: Stomach disease DIS5L3HQ: Esophageal disorder DISQ8G5S: Gastroesophageal reflux disease
ICD Code	ICD-11 ICD-11: DA22.Z Expand ICD-11 'DA22.Z Expand ICD-9 140,141,142,143,144,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000,000
Disease Identifiers	MONDO ID MONDO_0007186 MESH ID D005764 UMLS CUI C0017168 OMIM ID 109350 MedGen ID 6553 SNOMED CT ID 235595009

Drug-Interaction Atlas (DIA) of This Disease

Drug-Interaction Atlas (DIA)

This Disease is Treated as An Indication in 4 Approved Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
Cisapride	DMY7PED	Approved	Small molecular drug	[1]
Omeprazole	DM471KJ	Approved	Small molecular drug	[2]
Pantoprazole	DMSVOCZ	Approved	Small molecular drug	[3]
Vonoprazan	DMO6315	Approved	Small molecular drug	[4]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 6 Clinical Trial Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
RQ-00000004	DM9T8OF	Phase 3	NA	[5]
Myo-inositol hexaphosphate	DME2CAK	Phase 2/3	Small molecular drug	[6]
PF-885706	DM0KRLJ	Phase 2	NA	[7]
API-023	DM6P93J	Phase 1	NA	[8]
KOS-2187	DM4953W	Phase 1	Small molecular drug	[9]
M-0004	DMK7UNL	Phase 1	NA	[10]
------------------------------------------------------------------------------------


⏷ Show the Full List of 6 Drug(s)

This Disease is Treated as An Indication in 10 Discontinued Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
AZD1386	DMFAG8W	Discontinued in Phase 2	Small molecular drug	[11]
AZD2066	DMHP6OY	Discontinued in Phase 2	Small molecular drug	[12]
AZD3355	DMT5ZK3	Discontinued in Phase 2	Small molecular drug	[13]
Lavoltidine	DMTY5VE	Discontinued in Phase 2	Small molecular drug	[14]
Naronapride	DM8BHL6	Discontinued in Phase 2	Small molecular drug	[15]
Norcisapride	DMJSKUI	Discontinued in Phase 2	Small molecular drug	[16]
AZD-6538	DMQMGMZ	Discontinued in Phase 1	Small molecular drug	[17]
AZD-9343	DM1ZVO3	Discontinued in Phase 1	NA	[18]
CS-526	DMXKB8V	Discontinued in Phase 1	NA	[19]
PF-2391677	DMPTK2P	Discontinued in Phase 1	NA	[20]
------------------------------------------------------------------------------------


⏷ Show the Full List of 10 Drug(s)

This Disease is Treated as An Indication in 4 Preclinical Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
ADX-71943	DMEWFOL	Preclinical	NA	[21]
AZD-9335	DM0LWPJ	Preclinical	NA	[22]
JNJ-26070109	DMSXOPE	Preclinical	Small molecular drug	[23]
NHP-229	DM8H2QV	Preclinical	NA	[24]
------------------------------------------------------------------------------------

This Disease is Treated as An Indication in 3 Investigative Drug(s)

Drug Name	Drug ID	Highest Status	Drug Type	REF
CW-343	DM78IDQ	Investigative	NA	[6]
REC-0467	DMC31KT	Investigative	NA	[6]
RQ-00201894	DM4T8KV	Investigative	NA	[25]
------------------------------------------------------------------------------------

Molecular Interaction Atlas (MIA) of This Disease

Molecular Interaction Atlas (MIA)

This Disease Is Related to 17 DTT Molecule(s)

Gene Name	DTT ID	Evidence Level	Mode of Inheritance	REF
GAST	TT4LRVO	Limited	Altered Expression	[26]
ABAT	TTT2LD9	moderate	Biomarker	[27]
APOA4	TTNC3WS	Strong	Biomarker	[28]
APOB	TTN1IE2	Strong	Genetic Variation	[29]
CYP2C19	TTZ58XG	Strong	Genetic Variation	[30]
DPYD	TTZPS91	Strong	Genetic Variation	[29]
F2RL1	TTQR74A	Strong	Biomarker	[31]
FUT3	TTUPAD7	Strong	Genetic Variation	[32]
GNE	TT4DP5S	Strong	Altered Expression	[33]
GRM8	TT0IFKL	Strong	Genetic Variation	[29]
MAD1L1	TTNE9U7	Strong	Genetic Variation	[29]
MAP2K2	TT8H9GB	Strong	Altered Expression	[34]
PDE4B	TTVIAT9	Strong	Genetic Variation	[29]
PPY	TTIB95A	Strong	Altered Expression	[35]
TOP2B	TT4NVEM	Strong	Biomarker	[36]
TRPV1	TTMI6F5	Strong	Biomarker	[37]
PTGS2	TTVKILB	Definitive	Biomarker	[38]
------------------------------------------------------------------------------------


⏷ Show the Full List of 17 DTT(s)

This Disease Is Related to 2 DTP Molecule(s)

Gene Name	DTP ID	Evidence Level	Mode of Inheritance	REF
SLC52A1	DT7NOKR	Limited	Altered Expression	[39]
SLC4A7	DT03V27	Strong	Biomarker	[36]
------------------------------------------------------------------------------------

This Disease Is Related to 2 DME Molecule(s)

Gene Name	DME ID	Evidence Level	Mode of Inheritance	REF
SCLY	DEH4TD6	Limited	Genetic Variation	[40]
HIF1AN	DEY1CBW	Strong	Genetic Variation	[41]
------------------------------------------------------------------------------------

This Disease Is Related to 50 DOT Molecule(s)

Gene Name	DOT ID	Evidence Level	Mode of Inheritance	REF
CCL26	OT2B7HR9	Limited	Altered Expression	[42]
CHD7	OTHNIZWZ	Limited	Genetic Variation	[43]
CYLD	OT37FKH0	Limited	Genetic Variation	[44]
ECI1	OTRQTK84	Limited	Genetic Variation	[45]
TAL1	OTX4K6QZ	Limited	Genetic Variation	[40]
MEIS2	OTG4ADLM	moderate	Biomarker	[46]
RO60	OTLGM5A8	moderate	Biomarker	[47]
TAC1	OTM842YW	moderate	Altered Expression	[48]
ADAMTS17	OTCFITM9	Strong	Genetic Variation	[49]
AFF3	OTR0705Z	Strong	Genetic Variation	[29]
ANO10	OTG3BNOU	Strong	Genetic Variation	[29]
ARL2BP	OT7REEDA	Strong	Biomarker	[50]
ATP2A3	OTFYDEES	Strong	Biomarker	[51]
BARX1	OT2VP73H	Strong	Genetic Variation	[49]
BEST3	OTMY8G20	Strong	Genetic Variation	[52]
BSND	OTYWZWPD	Strong	Biomarker	[50]
BTN2A1	OTUYPMZJ	Strong	Genetic Variation	[29]
CAPN14	OTWKW0Y6	Strong	Altered Expression	[53]
CDX1	OTOHTMJE	Strong	Biomarker	[54]
CDX2	OTCG4TSY	Strong	Biomarker	[55]
CPSF4	OT53UK5L	Strong	Biomarker	[56]
CRNN	OTAORBR4	Strong	Biomarker	[57]
CTSW	OTXSBXFM	Strong	Altered Expression	[58]
DKK4	OTWCCVF6	Strong	Biomarker	[59]
FOXP2	OTVX6A59	Strong	Genetic Variation	[29]
GABRA6	OTX4UC3O	Strong	Genetic Variation	[60]
GSTT2	OTANW3TJ	Strong	Altered Expression	[61]
KLHL26	OTBKMANX	Strong	Genetic Variation	[29]
LCN1	OT8BWXTV	Strong	Biomarker	[62]
MAML3	OTZFV53Z	Strong	Genetic Variation	[29]
MCF2L2	OTOGFMIH	Strong	Biomarker	[63]
NPNT	OTFZAO1G	Strong	Biomarker	[64]
NTM	OTHF0UQU	Strong	Biomarker	[65]
PELI1	OTMLBCLC	Strong	Biomarker	[66]
PERP	OTP0YL53	Strong	Genetic Variation	[67]
PIGA	OT51UWUR	Strong	Genetic Variation	[68]
PRDM6	OTKY12D9	Strong	Biomarker	[66]
RAB5B	OT06PN42	Strong	Genetic Variation	[29]
RASL12	OTNAK9X4	Strong	Biomarker	[69]
RBM43	OTANIFBG	Strong	Genetic Variation	[70]
RNASE2	OT8Z4FNE	Strong	Biomarker	[71]
SAFB	OTGRV2LW	Strong	Biomarker	[72]
SCNN1D	OTTX2G9M	Strong	Biomarker	[73]
SDK1	OTX26906	Strong	Genetic Variation	[29]
SLC22A18	OT9C3KR4	Strong	Biomarker	[72]
SNRK	OTX0OPHO	Strong	Genetic Variation	[29]
TFF2	OTRXB19X	Strong	Biomarker	[74]
TFF3	OTJJDRTU	Strong	Biomarker	[74]
TP63	OT0WOOKQ	Strong	Biomarker	[75]
TRIM21	OTA4UJCF	Definitive	Biomarker	[47]
------------------------------------------------------------------------------------


⏷ Show the Full List of 50 DOT(s)

References

1	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 240).
2	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 4279).
3	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7260).
4	ClinicalTrials.gov (NCT02388724) Efficacy and Safety of Oral Once-Daily Vonoprazan (TAK-438) in Patients With Erosive Esophagitis. U.S. National Institutes of Health.
5	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800033657)
6	The ChEMBL database in 2017. Nucleic Acids Res. 2017 Jan 4;45(D1):D945-D954.
7	ClinicalTrials.gov (NCT00730665) Efficacy And Safety Of PF-00885706 For The Relief Of Symptoms In Subjects With Gastro-esophageal Reflux Disease (GERD). U.S. National Institutes of Health.
8	ClinicalTrials.gov (NCT00325715) AGN 201904 Versus Esomeprazole in the Prevention of Aspirin-induced Stomach or Upper Intestinal Damage in Healthy Volunteers. U.S. National Institutes of Health.
9	Emerging drugs for postoperative ileus. Expert Opin Emerg Drugs. 2007 Nov;12(4):619-26.
10	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800026666)
11	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7820).
12	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800027605)
13	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 7705).
14	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800000092)
15	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800019926)
16	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800007174)
17	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6440).
18	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800018389)
19	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800015294)
20	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028696)
21	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024111)
22	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800024134)
23	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Ligand id: 6665).
24	Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800040390)
25	URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 297).
26	Efficacy of long-term maintenance therapy with 10-mg vonoprazan for proton pump inhibitor-resistant reflux esophagitis.Esophagus. 2019 Oct;16(4):377-381. doi: 10.1007/s10388-019-00676-x. Epub 2019 May 22.
27	4-aminobutyrate aminotransferase (ABAT): genetic and pharmacological evidence for an involvement in gastro esophageal reflux disease.PLoS One. 2011 Apr 28;6(4):e19095. doi: 10.1371/journal.pone.0019095.
28	Duodenal lipid-induced symptom generation in gastroesophageal reflux disease: role of apolipoprotein A-IV and cholecystokinin.Neurogastroenterol Motil. 2012 Apr;24(4):350-e168. doi: 10.1111/j.1365-2982.2012.01880.x. Epub 2012 Feb 2.
29	Gastroesophageal reflux GWAS identifies risk loci that also associate with subsequent severe esophageal diseases.Nat Commun. 2019 Sep 16;10(1):4219. doi: 10.1038/s41467-019-11968-2.
30	Genotype tailored treatment of mild symptomatic acid reflux in children with uncontrolled asthma (GenARA): Rationale and methods.Contemp Clin Trials. 2019 Mar;78:27-33. doi: 10.1016/j.cct.2019.01.009. Epub 2019 Jan 16.
31	Mucosal Two-Step Pathogenesis in Gastroesophageal Reflux Disease: Repeated Weakly Acidic Stimulation and Activation of Protease-Activated Receptor-2 on Mucosal Interleukin-8 Secretion.Digestion. 2018;98(1):19-25. doi: 10.1159/000486480. Epub 2018 Apr 19.
32	Updated Systematic Review of Achalasia, with a Focus on POEM Therapy.Dig Dis Sci. 2020 Jan;65(1):38-65. doi: 10.1007/s10620-019-05784-3. Epub 2019 Aug 27.
33	Proteomics of acquired pellicle in gastroesophageal reflux disease patients with or without erosive tooth wear.J Dent. 2019 Feb;81:64-69. doi: 10.1016/j.jdent.2018.12.007. Epub 2018 Dec 21.
34	Differences in activity and phosphorylation of MAPK enzymes in esophageal squamous cells of GERD patients with and without Barrett's esophagus.Am J Physiol Gastrointest Liver Physiol. 2008 Sep;295(3):G470-8. doi: 10.1152/ajpgi.90262.2008. Epub 2008 Jul 10.
35	Association of serum gastric inhibitory polypeptide and pancreatic polypeptide levels with prolonged esophageal acid exposure time in refractory gastroesophageal reflux disease.Medicine (Baltimore). 2019 Jun;98(23):e15965. doi: 10.1097/MD.0000000000015965.
36	Transcript map of the candidate region for HSNI with cough and gastroesophageal reflux on chromosome 3p and exclusion of candidate genes.Neurogenetics. 2004 Sep;5(3):197-200. doi: 10.1007/s10048-004-0185-0. Epub 2004 Jul 6.
37	Generation and Characterization of an Immortalized Human Esophageal Myofibroblast Line.PLoS One. 2016 Apr 7;11(4):e0153185. doi: 10.1371/journal.pone.0153185. eCollection 2016.
38	A case-control study of the risk of upper gastrointestinal mucosal injuries in patients prescribed concurrent NSAIDs and antithrombotic drugs based on data from the Japanese national claims database of 13 million accumulated patients.J Gastroenterol. 2018 Dec;53(12):1253-1260. doi: 10.1007/s00535-018-1483-x. Epub 2018 Jun 12.
39	Increased TRPV1 and PAR2 mRNA expression levels are associated only with the esophageal reflux symptoms, but not with the extraesophageal reflux sy... Medicine (Baltimore). 2016 Aug;95(32):e4387.
40	Independent factors associated with the impact of gastroesophageal reflux disease on health-related quality of life.Rev Esp Enferm Dig. 2019 Feb;111(2):94-100. doi: 10.17235/reed.2018.5752/2018.
41	Interactions between environmental factors and polymorphisms in angiogenesis pathway genes in esophageal adenocarcinoma risk: a case-only study.Cancer. 2012 Feb 1;118(3):804-11. doi: 10.1002/cncr.26325. Epub 2011 Jul 12.
42	Omeprazole blocks eotaxin-3 expression by oesophageal squamous cells from patients with eosinophilic oesophagitis and GORD.Gut. 2013 Jun;62(6):824-32. doi: 10.1136/gutjnl-2012-302250. Epub 2012 May 12.
43	Phenotypic Spectrum of Idiopathic Hypogonadotropic Hypogonadism Patients With CHD7 Variants From a Large Chinese Cohort.J Clin Endocrinol Metab. 2020 May 1;105(5):dgz182. doi: 10.1210/clinem/dgz182.
44	Esophageal Adenocarcinoma After Antireflux Surgery in a Cohort Study From the 5 Nordic Countries.Ann Surg. 2021 Dec 1;274(6):e535-e540. doi: 10.1097/SLA.0000000000003709.
45	Tailored modern GERD therapy - steps towards the development of an aid to guide personalized anti-reflux surgery.Sci Rep. 2019 Dec 16;9(1):19174. doi: 10.1038/s41598-019-55510-2.
46	De novo MEIS2 mutation causes syndromic developmental delay with persistent gastro-esophageal reflux. J Hum Genet. 2016 Sep;61(9):835-8. doi: 10.1038/jhg.2016.54. Epub 2016 May 26.
47	Prevalence and clinical characteristics of overactive bladder in systemic sclerosis.Mod Rheumatol. 2020 Mar;30(2):327-331. doi: 10.1080/14397595.2019.1589913. Epub 2019 Apr 1.
48	Effect of anti-reflux treatment on gastroesophageal reflux-associated chronic cough: Implications of neurogenic and neutrophilic inflammation.J Asthma. 2020 Nov;57(11):1202-1210. doi: 10.1080/02770903.2019.1641204. Epub 2019 Jul 15.
49	Polymorphisms of the BARX1 and ADAMTS17 Locus Genes in Individuals With Gastroesophageal Reflux Disease.J Neurogastroenterol Motil. 2019 Jul 1;25(3):436-441. doi: 10.5056/jnm18183.
50	Pharmacological treatments for functional nausea and functional dyspepsia in children: a systematic review.Expert Rev Clin Pharmacol. 2018 Dec;11(12):1195-1208. doi: 10.1080/17512433.2018.1540298. Epub 2018 Dec 6.
51	Whole genome expression array profiling highlights differences in mucosal defense genes in Barrett's esophagus and esophageal adenocarcinoma.PLoS One. 2011;6(7):e22513. doi: 10.1371/journal.pone.0022513. Epub 2011 Jul 28.
52	Barrett's oESophagus trial 3 (BEST3): study protocol for a randomised controlled trial comparing the Cytosponge-TFF3 test with usual care to facilitate the diagnosis of oesophageal pre-cancer in primary care patients with chronic acid reflux.BMC Cancer. 2018 Aug 3;18(1):784. doi: 10.1186/s12885-018-4664-3.
53	Pathophysiology of Eosinophilic Esophagitis.Gastroenterology. 2018 Jan;154(2):333-345. doi: 10.1053/j.gastro.2017.06.065. Epub 2017 Jul 27.
54	Single nucleotide polymorphisms of caudal type homeobox 1 and 2 are associated with Barrett's esophagus.Dig Dis Sci. 2014 Jan;59(1):57-63. doi: 10.1007/s10620-013-2804-9. Epub 2013 Aug 6.
55	CDX-2 Expression in Esophageal Biopsies Without Goblet Cell Intestinal Metaplasia May Be Predictive of Barrett's Esophagus.Dig Dis Sci. 2020 Jul;65(7):1992-1998. doi: 10.1007/s10620-019-05914-x. Epub 2019 Nov 5.
56	Reflux episodes and esophageal impedance levels in patients with typical and atypical symptoms of gastroesophageal reflux disease.Medicine (Baltimore). 2017 Sep;96(37):e7978. doi: 10.1097/MD.0000000000007978.
57	An animal model to evaluate the function and regulation of the adaptively evolving stress protein SEP53 in oesophageal bile damage responses.Cell Stress Chaperones. 2008 Sep;13(3):375-85. doi: 10.1007/s12192-008-0037-1. Epub 2008 May 9.
58	Expression pattern of cathepsin W isoforms in peripheral blood and gastroesophageal mucosa of patients with gastroesophageal reflux disease.Biol Chem. 2011 Dec;392(12):1167-72. doi: 10.1515/BC.2011.192.
59	Dickkopf homologs in squamous mucosa of esophagitis patients are overexpressed compared with Barrett's patients and healthy controls.Am J Gastroenterol. 2006 Jul;101(7):1437-48. doi: 10.1111/j.1572-0241.2006.00584.x.
60	GABRA6 genetic polymorphism is associated with the risk of functional heartburn in Chinese.J Gastroenterol Hepatol. 2007 Feb;22(2):227-33. doi: 10.1111/j.1440-1746.2006.04441.x.
61	Constitutively Higher Level of GSTT2 in Esophageal Tissues From African Americans Protects Cells Against DNA Damage.Gastroenterology. 2019 Apr;156(5):1404-1415. doi: 10.1053/j.gastro.2018.12.004. Epub 2018 Dec 19.
62	Sputum proteomic signature of gastro-oesophageal reflux in patients with severe asthma.Respir Med. 2019 Apr;150:66-73. doi: 10.1016/j.rmed.2019.02.008. Epub 2019 Feb 11.
63	Cough reflex sensitivity does not correlate with the esophageal sensitivity to acid in patients with gastroesophageal reflux disease.Respir Physiol Neurobiol. 2018 Nov;257:25-29. doi: 10.1016/j.resp.2018.03.011. Epub 2018 Mar 27.
64	The 2years' long-term efficacy and safety of peroral endoscopic myotomy for the treatment of achalasia: a systematic review.J Cardiothorac Surg. 2019 Jan 3;14(1):1. doi: 10.1186/s13019-018-0811-9.
65	Adult Patients With Bronchiectasis: A First Look at the US Bronchiectasis Research Registry.Chest. 2017 May;151(5):982-992. doi: 10.1016/j.chest.2016.10.055. Epub 2016 Nov 23.
66	PRISM, a Patient-Reported Outcome Instrument, Accurately Measures Symptom Change in Refractory Gastroesophageal Reflux Disease.Dig Dis Sci. 2017 Mar;62(3):593-606. doi: 10.1007/s10620-016-4440-7. Epub 2017 Jan 23.
67	Interactions between genetic polymorphisms in the apoptotic pathway and environmental factors on esophageal adenocarcinoma risk.Carcinogenesis. 2011 Apr;32(4):502-6. doi: 10.1093/carcin/bgq287. Epub 2011 Jan 6.
68	Developing a blood-based gene mutation assay as a novel biomarker for oesophageal adenocarcinoma.Sci Rep. 2019 Mar 26;9(1):5168. doi: 10.1038/s41598-019-41490-w.
69	Correlation between the reflux finding score and the GERD impact scale in patients with gastroesophageal reflux disease.J Biol Regul Homeost Agents. 2018 Jul-Aug;32(4):989-993.
70	Interactions Between Genetic Variants and Environmental Factors Affect Risk of Esophageal Adenocarcinoma and Barrett's Esophagus.Clin Gastroenterol Hepatol. 2018 Oct;16(10):1598-1606.e4. doi: 10.1016/j.cgh.2018.03.007. Epub 2018 Mar 15.
71	Blind esophageal brushing offers a safe and accurate method to monitor inflammation in children and young adults with eosinophilic esophagitis.Dis Esophagus. 2018 Dec 1;31(12). doi: 10.1093/dote/doy056.
72	HCl-induced and ATP-dependent upregulation of TRPV1 receptor expression and cytokine production by human esophageal epithelial cells.Am J Physiol Gastrointest Liver Physiol. 2012 Sep 1;303(5):G635-45. doi: 10.1152/ajpgi.00097.2012. Epub 2012 Jul 12.
73	Epithelial Na+ channel delta subunit is an acid sensor in the human oesophagus.Eur J Pharmacol. 2008 Dec 14;600(1-3):32-6. doi: 10.1016/j.ejphar.2008.10.022. Epub 2008 Oct 18.
74	Possible application of trefoil factor family peptides in gastroesophageal reflux and Barrett's esophagus.Peptides. 2019 May;115:27-31. doi: 10.1016/j.peptides.2019.02.007. Epub 2019 Mar 1.
75	A conserved Pbx-Wnt-p63-Irf6 regulatory module controls face morphogenesis by promoting epithelial apoptosis.Dev Cell. 2011 Oct 18;21(4):627-41. doi: 10.1016/j.devcel.2011.08.005. Epub 2011 Oct 6.